Canaccord Genuity Downgrades Synageva BioPharma (GEVA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Nomura Securities Downgrades Synageva BioPharma (GEVA) to Neutral Amid Takeover
May 7, 2015 8:54 AM EDTNomura Securities downgraded Synageva BioPharma (NASDAQ: GEVA) from Buy to Neutral with a price target of $230.00 following the takeover deal.
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $203.39 yesterday.
... MoreBaird Downgrades Synageva BioPharma (GEVA) to Neutral
May 7, 2015 8:35 AM EDTBaird downgraded Synageva BioPharma (NASDAQ: GEVA) from Outperform to Neutral with a price target of $217.00 (from $115.00).
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $203.39 yesterday.
... MoreAlexion Pharma (ALXN) to Acquire Synageva BioPharma (GEVA) for $230/Share
May 6, 2015 6:40 AM EDTAlexion Pharma (NASDAQ: ALXN) and Synageva BioPharma Corp. (Nasdaq: GEVA) announced that they have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015. The acquisition strengthens Alexions global leadership in developing and commercializing transformative therapies for patients with devastating and rare diseases.
The transaction has been unanimously approved by both... More
